NeoGenomics Reports First Quarter 2024 Results [Yahoo! Finance]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Yahoo! Finance
Company , a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights Consolidated revenue increased 14% to $156 million Clinical Services revenue increased 17% to $135 million Advanced Diagnostics revenue decreased 3% to $22 million Net loss decreased 12% to $27 million Adjusted EBITDA was positive $3 million, an increase of 149% or $11 million "NeoGenomics had a strong start to 2024, with first quarter revenue growth of 14% year-over-year driven by solid execution and teamwork across our organization," said Chris Smith, CEO of NeoGenomics. "We're pleased with our performance, highlighted by another consecutive quarterly improvement in revenue per test and increased adoption of our NGS products. We remain confident in our ability to execute on our growth plans this year based on our progress." First-Quarter Results Consolidated revenue for the first quarter of
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- Kathryn McKenzie is Superfeet's New CFO — And the Third Woman in Shoes Named to the Top Finance Role This Week [Yahoo! Finance]Yahoo! Finance
- Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024 [Yahoo! Finance]Yahoo! Finance
- NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- NeoGenomics, Inc. (NASDAQ: NEO) had its price target lowered by analysts at BTIG Research from $23.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- NeoGenomics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 4/30/24 - Beat
NEO
Sec Filings
- 5/17/24 - Form 4
- 5/15/24 - Form 144
- 5/14/24 - Form 4
- NEO's page on the SEC website